Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591
(914) 847-7000Website: https://www.regeneron.com/Careers: https://careers.regeneron.com
Latest News
- New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19 - November 8, 2021
- FDA Expands Approval of Dupixent (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma - October 20, 2021
- FDA Accepts REGEN-COV (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19 - October 14, 2021
- New REGEN-COV (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19 - September 30, 2021
- Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail - September 14, 2021
- New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection - August 4, 2021
- FDA Expands Authorized Use of REGEN-COV (casirivimab and imdevimab) - July 30, 2021
- REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2 - June 16, 2021
- FDA Authorizes Lower 1,200 mg Intravenous and Subcutaneous Dose of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail to Treat Patients with COVID-19 - June 4, 2021
- Phase 3 Data Presented at ATS 2021 Show REGEN-COV™ (casirivimab with imdevimab) Reduced Risk of Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients - May 17, 2021
Drugs Associated with Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. manufactures, markets and/or distributes more than 7 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Arcalyst
Generic name: rilonacept Drug class: interleukin inhibitors |
2 reviews | 10 / 10 |
|
Dupixent
Generic name: dupilumab Drug class: interleukin inhibitors |
256 reviews | 6.9 / 10 |
|
Evkeeza
Generic name: evinacumab Drug class: miscellaneous antihyperlipidemic agents |
||
|
Eylea
Generic name: aflibercept Drug class: anti-angiogenic ophthalmic agents |
34 reviews | 6.3 / 10 |
|
Kevzara
Generic name: sarilumab Drug class: antirheumatics, interleukin inhibitors |
14 reviews | 4.8 / 10 |
|
Libtayo
Generic name: cemiplimab Drug class: anti-PD-1 monoclonal antibodies |
1 review | 10 / 10 |
|
Praluent
Generic name: alirocumab Drug class: PCSK9 inhibitors |
142 reviews | 5.9 / 10 |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||